Skip to content

Study · Animal study (in vivo) · dog · 2003

2 results

Comparative response of plasma VWF in dogs to up-regulation of VWF mRNA by interleukin-11 versus Weibel-Palade body release by desmopressin (DDAVP).

Olsen EH, McCain AS, Merricks EP, Fischer TH, Dillon IM, Raymer RA, Bellinger DA, Fahs SA, Montgomery RR, Keith JC Jr, Schaub RG, Nichols TC

Blood20 Mar 2003Cited by 31 (Europe PMC)

PMID12649145 (opens in a new tab)DOI10.1182/blood-2003-01-0290 (opens in a new tab)PepBankPUB-12649145
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Mechanism

    In VWD and normal dogs, DDAVP rapidly but transiently increased VWF, whereas rhIL-11 produced a gradual sustained increase.

    In plain wordsIn dogs, DDAVP rapidly but briefly increased VWF, whereas rhIL-11 produced a gradual sustained increase.

    Peptide
    Desmopressin
    Outcome
    IncreaseVWF levels
    Study

    dogn: not reported in source

    Heterozygous von Willebrand disease and normal dogs
    Comparator
    rhIL-11
    Outcome group
    Bleeding and clotting · Cardiovascular
    Studied dose
    5 microg/kg/d · intravenous · 7 daysAs given in this study (dog).

    Source sentences

    Summary
    The rhIL-11 produced a gradual and sustained elevation of VWF and FVIII levels in both heterozygous VWD and normal dogs while DDAVP produced a rapid and unsustained increase.
    1 context sentence
    Summary · context
    To compare the effect of these 2 agents, heterozygous von Willebrand disease (VWD) and normal dogs were treated with either rhIL-11 (50 microg/kg/d subcutaneously x 7 days) or DDAVP (5 microg/kg/d intravenously x 7 days).
  2. 02AnimalAnimal study (in vivo)Mechanism

    In VWD and normal dogs, DDAVP rapidly but transiently increased FVIII, whereas rhIL-11 produced a gradual sustained increase.

    In plain wordsIn dogs, DDAVP rapidly but briefly increased FVIII, whereas rhIL-11 produced a gradual sustained increase.

    Peptide
    Desmopressin
    Outcome
    IncreaseFVIII levels
    Study

    dogn: not reported in source

    Heterozygous von Willebrand disease and normal dogs
    Comparator
    rhIL-11
    Outcome group
    Bleeding and clotting · Cardiovascular
    Studied dose
    5 microg/kg/d · intravenous · 7 daysAs given in this study (dog).

    Source sentences

    Summary
    The rhIL-11 produced a gradual and sustained elevation of VWF and FVIII levels in both heterozygous VWD and normal dogs while DDAVP produced a rapid and unsustained increase.
    1 context sentence
    Summary · context
    To compare the effect of these 2 agents, heterozygous von Willebrand disease (VWD) and normal dogs were treated with either rhIL-11 (50 microg/kg/d subcutaneously x 7 days) or DDAVP (5 microg/kg/d intravenously x 7 days).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.